NCT04693429View on ClinicalTrials.gov

Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

November 27, 2020

Study Completion Date

December 8, 2020

Conditions
SafetyTolerabilityOcular SurfaceOcular Comfort
Interventions
DRUG

Bepotastine Besilate

Bepotastine Besilate 1.5% QID (quater in die) for 7 days

Trial Locations (1)

44190

Unidad Clínica de Bioequivalencia, S. de R.L. de C.V., Guadalajara

All Listed Sponsors
lead

Laboratorios Sophia S.A de C.V.

INDUSTRY

NCT04693429 - Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ | Biotech Hunter | Biotech Hunter